“I was scared about my eye injury, but they explained everything and helped me not worry.”
When to Refer Diabetic Patients for Retina Care
Who Is Affected and What Raises the Risk
Diabetic retinopathy affects a significant portion of people living with diabetes. Identifying patients at higher risk can help providers prioritize earlier screening and more frequent monitoring before vision loss occurs.
Millions of Americans with diabetes have some form of diabetic retinopathy, and a meaningful percentage have disease severe enough to threaten vision. The number of people affected is expected to grow substantially as rates of diabetes continue to rise. Many patients do not know they have retinal changes until damage has already occurred.
Several factors increase the likelihood that a person with diabetes will develop retinopathy. Being aware of these helps identify patients who may need earlier or more frequent screening.
- Duration of diabetes: people who have had diabetes for 15 or more years are at significantly higher risk for retinopathy and severe disease
- Chronic high blood sugar and poor glycemic control
- High blood pressure (hypertension)
- High cholesterol and other lipid abnormalities (dyslipidemia)
- Kidney disease (nephropathy)
Among people newly diagnosed with diabetes, a notable percentage may already have early signs of retinopathy at the time of diagnosis, which underscores the importance of screening at the point of diagnosis for type 2 diabetes.
Pregnant women with pre-existing diabetes face an increased risk of rapid progression of diabetic retinopathy. These patients should have a dilated eye exam early in pregnancy and be monitored closely throughout. Women who develop gestational diabetes, meaning diabetes that begins during pregnancy, do not require a separate eye exam for this condition alone.
Adolescents going through puberty may also experience accelerated progression of diabetic retinopathy. Closer follow-up during this developmental stage is important for this group as well.
There is growing evidence that rapid, tight blood sugar control may in some cases accelerate the early onset of diabetic retinopathy. This has been observed with newer glucose-lowering medications including semaglutide and similar agents. Patients starting these treatments may benefit from closer retinal monitoring, particularly if they previously had poorly controlled blood sugar levels.
Recognizing Signs and Symptoms
One of the most important things for patients and providers to understand is that diabetic retinopathy often causes no noticeable symptoms in its early stages. Knowing what to watch for, and when to act urgently, can protect a patient's vision.
In the early stages of diabetic retinopathy, many patients feel their vision is completely normal even when significant changes are occurring inside the eye. Damage can accumulate silently before any change in sight is noticed. This is the primary reason routine screening is so important for all people with diabetes.
As the disease progresses, patients may begin to notice changes in their vision. These can include blurred or fluctuating vision, dark spots or floaters, difficulty seeing in low light, and colors that appear faded or washed out. If diabetic macular edema develops, patients may notice that straight lines appear wavy or that reading becomes more difficult.
Certain symptoms indicate a serious problem that requires immediate evaluation. Patients experiencing any of the following should contact a retina specialist or seek emergency care right away.
- A sudden increase in floaters or new floaters that are large or numerous
- Flashes of light in one eye
- A shadow or dark curtain spreading across part of the vision
- Sudden vision loss in one eye
These symptoms could signal a vitreous hemorrhage (bleeding inside the eye) or a retinal detachment, both of which require prompt treatment to protect vision.
Diagnosis and Screening
Early detection of diabetic retinopathy depends on following appropriate screening schedules and using the right diagnostic tools. A retina specialist can also evaluate findings in greater detail when standard screening raises concerns.
People with type 1 diabetes should begin annual screening for diabetic retinopathy five years after their initial diagnosis. People with type 2 diabetes should have their first screening at the time of diagnosis, followed by at least annual exams thereafter. A retina specialist may recommend more frequent visits depending on the severity of any findings.
The standard method for detecting diabetic retinopathy is a comprehensive dilated eye exam. During this exam, drops are used to widen the pupil so the retina specialist can clearly see the inside of the eye. The specialist looks for microaneurysms, retinal bleeding, swelling, abnormal blood vessels, and other signs of damage.
When a more detailed evaluation is needed, a retina specialist may use advanced diagnostic tools. Optical coherence tomography (OCT) creates detailed cross-sectional images of the retina to detect and measure swelling and fluid. Fluorescein angiography uses a special dye injected into a vein to reveal leaking or blocked blood vessels. OCT angiography, wide-field imaging, and B-scan ultrasound may also be used depending on the clinical situation.
Treatment Options
Several effective treatments are available for diabetic retinopathy and diabetic macular edema. The right approach depends on the stage of the disease and the specific findings on examination and imaging. Our retina specialists use the full range of available therapies to protect and, in many cases, improve vision.
Anti-VEGF medications are the primary treatment for center-involved diabetic macular edema with vision loss and for proliferative diabetic retinopathy. These medications block vascular endothelial growth factor, the protein that drives abnormal blood vessel growth and leakage. They are delivered as intravitreal injections, meaning they are injected directly into the eye in a carefully controlled procedure.
Several anti-VEGF agents are used in retina care. Eylea (aflibercept) is commonly used and is typically given on a schedule that can extend to longer intervals after initial loading doses. Lucentis (ranibizumab) was among the first anti-VEGF medications approved for eye conditions. Vabysmo (faricimab) is a bispecific antibody that targets both VEGF and angiopoietin-2 and can be given at intervals of up to 16 weeks in appropriate patients.
Avastin (bevacizumab) is FDA-approved for certain cancer treatments but is widely used off-label by retina specialists for diabetic macular edema and diabetic retinopathy. It works through the same VEGF-blocking mechanism as other anti-VEGF agents. Patients should be aware that its use for eye conditions is off-label, meaning it is not specifically FDA-approved for this purpose, though it is a well-established and widely studied option.
Panretinal photocoagulation (PRP) is a laser treatment that remains an important option for proliferative diabetic retinopathy. During PRP, a retina specialist applies a pattern of small laser burns to the peripheral retina. This reduces the retina's demand for oxygen and helps slow the growth of abnormal blood vessels. Focal or grid laser treatment may also be used in selected cases of diabetic macular edema.
Vitrectomy is a surgical procedure in which the retina specialist removes the vitreous gel from inside the eye. It may be needed when there is significant bleeding into the vitreous that does not clear on its own, or when scar tissue is pulling on the retina and causing traction. During the procedure, blood, scar tissue, and vitreous gel are removed, and the eye is filled with a clear solution or gas bubble to support healing. This procedure is performed at our dedicated surgical facility.
What Patients Can Expect
Patients and referring providers often want to understand what treatment involves and what outcomes are realistic. Setting clear expectations helps patients stay engaged in their care over the long term.
When diabetic retinopathy is detected and treated early, current treatment strategies can be highly effective in preventing severe vision loss. Anti-VEGF injections can reduce the severity of diabetic retinopathy and in some cases lead to measurable improvement on imaging. However, outcomes depend significantly on how advanced the disease is when treatment begins, which is why timely referral matters.
Most anti-VEGF injection visits take less than an hour from start to finish. The eye is numbed with anesthetic drops before the injection to minimize discomfort. Patients may experience mild soreness, redness, or a feeling of pressure after the injection, and these effects typically resolve within a day or two. Most patients find the experience more manageable than they anticipated.
Diabetic retinopathy is a chronic condition that requires ongoing management, even after successful treatment. Regular follow-up visits allow a retina specialist to detect any recurrence or progression early and adjust treatment as needed. The frequency of follow-up is tailored to each patient based on the severity of their disease and how well they respond to treatment.
Living With Diabetic Retinopathy
Managing diabetic retinopathy goes beyond clinic visits. The choices patients make between appointments, including how they manage their blood sugar and whether they keep their eye exams, directly affect how the disease progresses over time.
Maintaining healthy blood sugar levels is one of the most powerful steps a person with diabetes can take to slow the progression of retinopathy. Working closely with a primary care provider or endocrinologist to manage blood sugar, blood pressure, and cholesterol provides important support for overall eye health. These efforts work alongside, rather than instead of, the treatments a retina specialist provides.
Staying on schedule with dilated eye exams is critical. Because diabetic retinopathy can worsen without causing symptoms, delaying or skipping appointments allows the disease to advance to a stage where treatment is less effective or options become more limited. Patients who notice any new vision changes between appointments should contact a retina specialist promptly rather than waiting for their next scheduled visit.
A diagnosis of diabetic retinopathy can understandably cause worry and frustration. Patients may benefit from connecting with diabetes support groups or low-vision rehabilitation services if their sight has been affected. A retina specialist can help guide patients toward available resources. Staying informed about the condition and actively participating in treatment decisions often helps patients feel more confident throughout their care.
When to Refer to a Retina Specialist
Knowing when to refer a diabetic patient for retina care is one of the most important decisions a primary care provider or optometrist can make. Clear referral criteria and urgency guidance help ensure patients receive appropriate care at the right time.
The following findings during a screening exam should prompt a referral to a retina specialist.
- Any level of macular edema detected on exam or imaging
- Severe nonproliferative diabetic retinopathy, which is a known precursor to the proliferative stage
- Any proliferative diabetic retinopathy, including the presence of new abnormal blood vessels
- Visual acuity worse than 20/40 or patient-reported symptomatic vision changes
- Neovascularization of the iris or angle, meaning new blood vessel growth in the front of the eye, which requires urgent referral
When in doubt, referring for a baseline evaluation by a retina specialist is always a reasonable and proactive step for any patient with diabetes who has not had a recent dilated exam.
Not all referrals carry the same level of urgency. High-risk proliferative diabetic retinopathy, defined by larger areas of new vessel growth on the optic disc or any new vessel growth accompanied by bleeding into the eye, should be referred within 24 to 48 hours. Lower-risk proliferative disease may be referred within two to four weeks. Patients with new blood vessel growth in the front part of the eye, a condition called anterior segment neovascularization, should be referred urgently because prompt treatment may prevent severe complications including neovascular glaucoma (a serious pressure condition caused by abnormal blood vessel growth).
Certain patients benefit from earlier or more frequent retinal evaluations beyond the standard annual schedule. These include pregnant women with pre-existing diabetes, adolescents going through puberty, and patients starting rapid glucose-lowering therapies such as semaglutide. Anyone with a history of poor blood sugar control or long-standing diabetes should also be considered for more proactive monitoring.
Frequently Asked Questions
The following questions address common concerns from patients and referring providers about diabetic retinopathy, referral decisions, and treatment expectations.
Yes, and this is one of the most important facts to communicate to patients. Significant retinal damage can develop and progress without any noticeable change in vision. This is why annual dilated eye exams are recommended for all people with diabetes, regardless of how well they feel they are seeing. By the time symptoms appear, the disease may already be at an advanced stage where treatment is more difficult and outcomes less predictable.
Progression varies considerably from person to person. In some patients, mild disease remains stable for years. In others, particularly those with poorly controlled blood sugar, high blood pressure, or elevated cholesterol, the condition can advance to a vision-threatening stage within months. Pregnancy, puberty, and rapid changes in glucose control can all accelerate progression. This variability is exactly why regular monitoring rather than a wait-and-see approach is recommended.
The eye is thoroughly numbed with anesthetic drops before each injection, so most patients describe feeling pressure or mild discomfort during the procedure rather than sharp pain. Some mild soreness, redness, or a gritty sensation may follow for a day or two. While the thought of receiving an injection in the eye is understandably concerning for many patients, most report that the actual experience is much more tolerable than they expected.
Without treatment, diabetic retinopathy can lead to permanent and severe vision loss. Proliferative disease can cause bleeding inside the eye, the formation of scar tissue, and retinal detachment. Diabetic macular edema, if left untreated, can destroy the central vision needed for reading, driving, and recognizing faces. The damage caused by advanced disease is often irreversible, which is why early detection and referral offer the best chance of preserving vision.
There is growing evidence that rapid improvement in blood sugar control from medications such as semaglutide may accelerate the development or progression of diabetic retinopathy in some patients, particularly those who previously had high or poorly controlled blood sugar. A baseline eye exam before starting these medications and more frequent monitoring during the first year of treatment may be appropriate. Patients should discuss this risk with both their diabetes care provider and a retina specialist so the right monitoring plan can be established from the start.
Absolutely. A retina specialist can perform a baseline evaluation for any patient with diabetes who has risk factors or has not had a recent dilated exam, even if no retinal changes have been identified yet. This kind of proactive referral is particularly valuable for patients with long-standing diabetes, poor glycemic control, or other compounding risk factors. A baseline evaluation establishes an important reference point for tracking any future changes.
Care for Diabetic Eye Disease on the Delmarva Peninsula
Atlantic Retina Center exclusively treats conditions of the retina, vitreous, and macula, giving our team a depth of experience that is difficult to find outside of a single-specialty practice. Our fellowship-trained, board-certified retina specialists are equipped with advanced imaging and the full range of treatments for diabetic retinopathy and diabetic macular edema. If you are a provider seeking to refer a patient, or a patient looking for expert retina care, we welcome you to reach out to our team and schedule an evaluation.